Breaking News

Seeing concentrations of toxins with the naked eye | NSF Governor Abbott To Appoint Senator Nelson As Texas Secretary Of State | Office of the Texas Governor Attorney General James Stops Illegal Agreement between Home Care Companies to Protect Patients and Caregivers Apple introduces Apple Music Sing CARNIVAL PLC – VOTING RIGHTS AND CAPITAL Administrator Samantha Power’s Meeting with Dr. Sohn Hyuk-Sang, President, Korea International Cooperation Agency | Readout Karen Rebaza Named New Deputy Director of Boston Home Center US Department of Labor ‘Star’ designation recognizes Bellingham and Blackstone Power Generation LLC for workplace safety, health excellence

GSK announces Q3 core EPS growth of 16% and dividend of 19p

  • Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies
  • Pharma & Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%,
  • Consumer Healthcare +4%
  • Four approvals in three markets; Tivicay for HIV and FluLaval Q-IV vaccine for flu; Tafinlar for metastatic melanoma; Relvar Ellipta for asthma
  • Q3 dividend of 19p (+6%)
  • Full year 2013 guidance reaffirmed

View full Q3 2013 results (PDF)

More information including including CFO interview are available in the quarterly results section of this website.

Source link